Navigation Links
Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
Date:7/15/2009

BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than patients given edoxaban twice a day (BID). The analysis finds that bleeding associated with edoxaban is most closely correlated with minimum concentration levels of the drug in the blood, and that these trough levels may best predict bleeding events, rather than total exposure or maximum concentration levels.

These findings were presented today at the XXII International Society on Thrombosis and Haemostasis Congress in Boston. Edoxaban is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568) as a potential treatment for the prevention of both arterial and venous thromboembolism; a Phase III trial is underway among patients with AF.

This pharmacokinetic (PK) analysis of the Phase IIb study examined the relationship between bleeding events reported in patients taking 30 or 60 mg edoxaban given either QD or BID and the concentration of edoxaban in their blood. The analysis examined overall bleeding rates when drug concentration levels reached the highest points (known as Cmax), lowest points (known as Cmin) as well as overall edoxaban exposure (measured by area under the curve or AUC). Delivering a compound twice per day generally allows for more consistent concentration levels in the blood. With twice-daily dosing, the Cmin levels (troughs) do not dip as low, and the Cmax levels (peaks) do not reach as high as when the compound is delivered once per day.

"When we assessed the pharmacokinetics in patients taking edoxaban once a day, lower minimum concentrations and fewer bleeding events were observed, compared to the same total daily dosage give
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/pw67sw/xray_market ) has announced ... Size, Share, Growth, Trends and Forecast 2014 - 2022" ... held the largest share of 34.6% of the ... Pacific and Europe . ... the U.S. and Canada that have ...
(Date:5/21/2015)... Kalifornien, und KOPENHAGEN, Dänemark, 21. Mai 2015 ... ein Weltmarktführer bei der klinischen und kommerziellen ... man werde im Rahmen der weltweiten Kapazitätserweiterungsstrategie ... 14.000 Liter Produktionskapazität erweitern. Logo ... erhalten durch das innovative Einweg Bioreactor 6Pack ...
(Date:5/21/2015)... BETHESDA, Md. , May 21, 2015 /PRNewswire-USNewswire/ ... an open innovation competition designed to bring promising ... the Heritage Provider Network (HPN) in collaboration with ... Center for Advancing Innovation (CAI).  The winning teams ... models and live pitches and will move forward ...
Breaking Medicine Technology:X-Ray Market: Global Industry Analysis 2014 - 2022 2CMC Biologics erweitert GMP-Produktionskapazität in Europa 2CMC Biologics erweitert GMP-Produktionskapazität in Europa 3Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 2Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 3Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 4
... second-tranche investment-, CAMBRIDGE, Mass., April 2, 2008 ... patient enrollment into its,Phase II clinical trial of ... osteoporosis. The Phase II dose-finding study is designed ... new bone for the treatment,of osteoporosis in postmenopausal ...
... LAUSANNE, Switzerland, and POMEZIA, Italy, April 2 ... Efficacy Results, Debiopharm Group (Debiopharm), a ... medical conditions, particularly,oncology and cardiology, and sigma-tau ... pharmaceutical group, today presented,positive efficacy results of ...
Cached Medicine Technology:Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis 2Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure 2Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure 3
(Date:5/21/2015)... 2015 Absolute Exhibits, a trade ... state-of-the-art website that is filled with essential exhibiting tools ... information. With its original and inventive design ideas, it ... website shows hundred of pictures of client- owned or ... is not an exhibit rendering site, rather real-time pictures ...
(Date:5/21/2015)... Ticket Down is a reliable source for authentic tickets to the ... Friday, July 3rd at LP Field in Nashville, TN. ... soccer. The number of chances to watch some of the best ... a large clip. Over the past several years, many of the ... in front of the American people. The match between the USA ...
(Date:5/21/2015)... How do you stop head lice epidemics ... and school administrators, but a Miami Lice Removal Company, Lice ... southern Florida, is devising new ways to stop the spread. ... you, the first step is education and prevention. Despite the ... and how they spread are still widely misunderstood. Many continue ...
(Date:5/21/2015)... York, New York (PRWEB) May 21, 2015 ... The Atmananda Yoga Studio and Sequence, is excited ... Atmananda Yoga Mat™, which was previously available for use ... Atmananda Yoga Mat™ unique is that it's mathematically ... prevent serious joint injuries and muscle strains, commonly ...
(Date:5/21/2015)... May 21, 2015 Amercanex today ... Exchange, the first fully electronic marketplace for industrial ... comprehensive electronic marketplace in which wholesale and retail ... their hemp-related inventories on a fully disclosed and ... this demand through a unique blend of cutting-edge ...
Breaking Medicine News(10 mins):Health News:New Convention and City Travel Guides Within the Absolute Exhibits’ Website 2Health News:USA vs. Guatemala Tickets: Ticket Down Slashes United States Men's Soccer Team (USMNT) vs. Guatemala Tickets at LP Field in Nashville on 7/3/15 2Health News:Local Lice Removal Company Partners with Schools to Combat Head Lice in the Classroom as Increase in Number of Cases Reported in May. 2Health News:NY's Atmananda Yoga Studio Launches Its Patented "Alignment" Yoga Mat for Public Sale 2Health News:Amercanex is Revolutionizing Order and Efficiency in the Hemp Industry 2
... a panic disorder may benefit more from treatment combining ... care usually offered by physicians. ,Panic disorder is ... In the study, 232 patients meeting the criteria for ... usual or a treatment combining medication and up to ...
... have not forgotten the thalidomide tragedy thalidomide in the 1950s ... sickness // to pregnant mothers and resulted in seal like ... use for the infamous medication: helping cancer patients maintain their ... in pancreatic cancer patients and was seen to help weight ...
... in Journal of Dental Research, caries in primary teeth may ... tooth can have caries for a wide variety of reasons ... of exposure to water fluoridation, disturbance to primary teeth, and ... can caries in primary teeth have long-term effect on the ...
... the recent issue of Journal of American Medical Association, researchers ... trend in delaying the vaccination schedules of the children resulting ... children. ,According to the latest study, most of ... two years of age in children often gets delayed due ...
... paper presented at American College of Cardiology, laughter can ... presenter of the paper Michael Miller, MD, director of ... medicine at the University of Maryland in Baltimore, had ... healthy and 150 people suffering cardiac problems. ,The ...
... have discovered a potential form of relief for patients ... million Americans are estimated to have ulcerative colitis or ... disease. The conditions, can be painful and debilitating, and ... with inflammatory bowel disease suffer bouts of watery diarrhea ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: